Search
00
GBAF Logo
trophy
Top StoriesInterviewsBusinessFinanceBankingTechnologyInvestingTradingVideosAwardsMagazinesHeadlinesTrends

Subscribe to our newsletter

Get the latest news and updates from our team.

Global Banking & Finance Review®

Global Banking & Finance Review® - Subscribe to our newsletter

Company

    GBAF Logo
    • About Us
    • Profile
    • Privacy & Cookie Policy
    • Terms of Use
    • Contact Us
    • Advertising
    • Submit Post
    • Latest News
    • Research Reports
    • Press Release
    • Awards▾
      • About the Awards
      • Awards TimeTable
      • Submit Nominations
      • Testimonials
      • Media Room
      • Award Winners
      • FAQ
    • Magazines▾
      • Global Banking & Finance Review Magazine Issue 79
      • Global Banking & Finance Review Magazine Issue 78
      • Global Banking & Finance Review Magazine Issue 77
      • Global Banking & Finance Review Magazine Issue 76
      • Global Banking & Finance Review Magazine Issue 75
      • Global Banking & Finance Review Magazine Issue 73
      • Global Banking & Finance Review Magazine Issue 71
      • Global Banking & Finance Review Magazine Issue 70
      • Global Banking & Finance Review Magazine Issue 69
      • Global Banking & Finance Review Magazine Issue 66
    Top StoriesInterviewsBusinessFinanceBankingTechnologyInvestingTradingVideosAwardsMagazinesHeadlinesTrends

    Global Banking & Finance Review® is a leading financial portal and online magazine offering News, Analysis, Opinion, Reviews, Interviews & Videos from the world of Banking, Finance, Business, Trading, Technology, Investing, Brokerage, Foreign Exchange, Tax & Legal, Islamic Finance, Asset & Wealth Management.
    Copyright © 2010-2026 GBAF Publications Ltd - All Rights Reserved. | Sitemap | Tags | Developed By eCorpIT

    Editorial & Advertiser disclosure

    Global Banking & Finance Review® is an online platform offering news, analysis, and opinion on the latest trends, developments, and innovations in the banking and finance industry worldwide. The platform covers a diverse range of topics, including banking, insurance, investment, wealth management, fintech, and regulatory issues. The website publishes news, press releases, opinion and advertorials on various financial organizations, products and services which are commissioned from various Companies, Organizations, PR agencies, Bloggers etc. These commissioned articles are commercial in nature. This is not to be considered as financial advice and should be considered only for information purposes. It does not reflect the views or opinion of our website and is not to be considered an endorsement or a recommendation. We cannot guarantee the accuracy or applicability of any information provided with respect to your individual or personal circumstances. Please seek Professional advice from a qualified professional before making any financial decisions. We link to various third-party websites, affiliate sales networks, and to our advertising partners websites. When you view or click on certain links available on our articles, our partners may compensate us for displaying the content to you or make a purchase or fill a form. This will not incur any additional charges to you. To make things simpler for you to identity or distinguish advertised or sponsored articles or links, you may consider all articles or links hosted on our site as a commercial article placement. We will not be responsible for any loss you may suffer as a result of any omission or inaccuracy on the website.

    Home > Finance > U.S. citizen jailed in Russia for 15 years leaked biotechnology secrets, FSB says
    Finance

    U.S. citizen jailed in Russia for 15 years leaked biotechnology secrets, FSB says

    Published by Global Banking & Finance Review®

    Posted on December 27, 2024

    2 min read

    Last updated: January 27, 2026

    This image depicts the Moscow court where U.S. citizen Eugene Spector was sentenced to 15 years for leaking biotechnology secrets to the U.S. government, emphasizing the espionage case's significance in finance and security.
    U.S. citizen Eugene Spector sentenced for espionage in Russia - Global Banking & Finance Review
    Why waste money on news and opinion when you can access them for free?

    Take advantage of our newsletter subscription and stay informed on the go!

    Subscribe

    Quick Summary

    Eugene Spector, a U.S. citizen, was sentenced to 15 years in Russia for espionage, accused of leaking biotechnology secrets to the U.S., according to the FSB.

    U.S. Citizen Sentenced to 15 Years in Russia for Espionage

    MOSCOW (Reuters) - Eugene Spector, a U.S. citizen jailed for a total of 15 years this week after a Moscow court convicted him of espionage, was found guilty of passing biotechnology secrets to the United States, Russia's FSB security service said on Friday.

    Russian state news agencies reported on Tuesday that Spector, who was born in Russia and then moved to the U.S., had been handed a 13-year jail sentence for spying. This was added to an existing bribery sentence and converted into a new 15-year jail term in a maximum security penal colony.

    State media did not say how Spector had pleaded to the charges in his closed-door trial.

    The details of the espionage case against him were not made public at the time either. But the FSB, the main successor of the Soviet-era KGB, said on Friday that Spector had been acting on behalf of the Pentagon.

    "The American, acting in the interests of the Pentagon and a commercial organisation affiliated with it, collected and transferred to a foreign party various information on biotechnological and biomedical topics, including those constituting state secrets, for the subsequent creation by the U.S. of a system of high-speed genetic screening of the Russian population," the FSB said in a statement.

    The FSB, which usually says if a defendant has confessed, did not say how Spector - who had already been serving a 3-1/2-year sentence in Russia for bribery - had pleaded.

    Before his 2021 arrest in the earlier case, Spector served as chairman of the board of Medpolymerprom Group, a company specialising in cancer-curing drugs, state media has said.

    In his first court case, Spector pleaded guilty to helping bribe an assistant to an ex-Russian deputy prime minister, according to Russian state media.

    (Reporting by Andrew Osborn; Editing by Gareth Jones)

    Key Takeaways

    • •Eugene Spector, a U.S. citizen, sentenced to 15 years in Russia.
    • •Convicted of passing biotechnology secrets to the U.S.
    • •FSB claims Spector acted on behalf of the Pentagon.
    • •Spector previously served a sentence for bribery.
    • •Details of the espionage case remain undisclosed.

    Frequently Asked Questions about U.S. citizen jailed in Russia for 15 years leaked biotechnology secrets, FSB says

    1What is the main topic?

    The article discusses the sentencing of U.S. citizen Eugene Spector in Russia for espionage, specifically for leaking biotechnology secrets.

    2Who is Eugene Spector?

    Eugene Spector is a U.S. citizen convicted in Russia for espionage, accused of passing biotechnology secrets to the U.S.

    3What was Spector accused of?

    Spector was accused of collecting and transferring biotechnology information to the U.S., acting on behalf of the Pentagon.

    More from Finance

    Explore more articles in the Finance category

    Image for French miner Eramet's finance chief steps aside temporarily, days after CEO ouster
    French miner Eramet's finance chief steps aside temporarily, days after CEO ouster
    Image for Ukraine's Zelenskiy calls for faster action on air defence, repairs to grid
    Ukraine's Zelenskiy calls for faster action on air defence, repairs to grid
    Image for Goldman Sachs teams up with Anthropic to automate banking tasks with AI agents, CNBC reports
    Goldman Sachs teams up with Anthropic to automate banking tasks with AI agents, CNBC reports
    Image for Analysis-Hims' $49 weight-loss pill rattles investor case for cash-pay obesity market
    Analysis-Hims' $49 weight-loss pill rattles investor case for cash-pay obesity market
    Image for Analysis-Glencore to focus on short-term disposals as Rio deal remains elusive
    Analysis-Glencore to focus on short-term disposals as Rio deal remains elusive
    Image for Belgium's Agomab Therapeutics valued at $716 million as shares fall in Nasdaq debut
    Belgium's Agomab Therapeutics valued at $716 million as shares fall in Nasdaq debut
    Image for Big Tech's quarter in four charts: AI splurge and cloud growth
    Big Tech's quarter in four charts: AI splurge and cloud growth
    Image for EU hikes tariffs on Chinese ceramics to 79% to counter dumping 
    EU hikes tariffs on Chinese ceramics to 79% to counter dumping 
    Image for AI trade splinters as investors get more selective
    AI trade splinters as investors get more selective
    Image for EU extends tariff suspension on $109.8 billion of US imports for six months
    EU extends tariff suspension on $109.8 billion of US imports for six months
    Image for Dog food maker Ollie acquired by Spain’s Agrolimen
    Dog food maker Ollie acquired by Spain’s Agrolimen
    Image for Salzgitter to take over HKM steel joint venture, end clash with Thyssenkrupp
    Salzgitter to take over HKM steel joint venture, end clash with Thyssenkrupp
    View All Finance Posts
    Previous Finance PostAzerbaijan Airlines says plane crash caused by 'external interference'
    Next Finance PostShell shuts down oil processing unit to investigate leak, Singapore's port authority says